Margarita Breakfast Club Session 1: Moving Forward: Upcoming Strategies on STI Prevention

Tuesday, February 20 at 7:00–8:00am PT

AVAC, the CROI Community Liaison Subcommittees, European AIDS Treatment Group, and other partners hosted virtual Margarita Breakfast Clubs (MBCs) for the 2023 CROI meeting. Speaker details, recording, and resources for the second 2023 MBC below.

  • Moderator: Ntando Yola, Desmond Tutu HIV Foundation
  • Speakers: Dr. Susan Buchbinder, San Francisco Department of Public Health, Richard Jefferys, Treatment Action Group

Recording / Slides

Ready, Set, CROI 2023 – Prepare for the 30th Year of CROI

Monday, February 13, 2023

Featured CROI Community Liaisons, CROI 2023 program co-chairs, IAS-USA, AVAC, The Choice Agenda, and other community partners and researchers and designed to help CROI registrants prepare for this exciting, intense and sometimes overwhelming meeting.
Recording / Slides

HIV Vaccines: An introductory factsheet

This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.

Px Wire July-September 2022, Vol. 12, No. 2

PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.

Access to the Dapivirine Vaginal Ring: A timeline on progress

Px Wire April-June 2022, Vol. 12, No. 1

Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.

A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)

AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.

AVAC Comments to FDA in Support of PrEP Approval

Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.

CAB-LA Trials at a Glance

This infographic shares a breakdown of the current injectable CAB for PrEP trials including ongoing sub-studies.

Time to Develop a Vaccine

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphic is excerpted from Vaccines by the Numbers: Trials, discoveries, money and more.